

Figure 1




Figure 2




FIGURE 3A




FIGURE 3B




Figure 3C




Figure 3D






Figure 4



**SUBSTITUTE SHEET (RULE 26)** 







Figure 7



C





Figure 8



## Strategy for Increasing Expression of IL-15 through Optimization of IL-15 DNA Constructs for Immunization

❖Primers are designed to amplify IL-15 from start of signal peptide, thus upstream inhibitory AUGs are not present in the final IL-15 message. ❖Primers are designed to include a strong KOZAK context (GCCGCCACC).

♦Removal of the C-terminus negative regulatory element using PCR antisense primer design

Primer Name	Sense/Antisense	Seguence 5' to 3'
Human IL-15 (LSP)	Serisë, (SEQ ID NO:4)	Sensé (SEQ ID NO:4) GCCCCCCGTCGAC GCCCCCACCATGAGAATTTCGAAACCACATTTGAG
	antisense(SEO ID NO:5)	Britisensesed ID NO:5/ATCGGGGTCGAG TCAAGAAGTGTTGATGAACATTTGG
Macaque IL-15 (LSP)	Sense (SEQ ID NO:4)	Sense (SEQ ID NO:4) GCCCCCGTCGAC GCCCCCACCATGAGAATTTCGAAACCACATTTGAG
	antisense(SEQ ID NO:5)	BINISBINSE(SEQ ID NO.5) AT CGGGCTCGAG TCAAGAAGTGTTGATGAACATTTGG
Human IL-15 (SSP)	Sense (SEQ ID NO:6)	Sense (SEQ ID NO:6) GCCCCCCGGGTACC GCCGCCACCATCGTATTGGGAACCATA
	antisense(SEQ ID NO:7)	antisensesed ID NO:7/ATCGGGGGATCCTCAAGAAGTGTTGATGAACAT
I goond Restriction Sit	SHE KOZAK START STOD COON	MOGOD GODS

FIGURE 10

BEST AVAILABLE COPY

## BEST AVAILABLE COPY

## Strategy for Increasing Expression of IL-15 through Replacement of 48 amino acid Signal Peptide (LSP) with IgE leader

Sense primers are designed to start after 48 aa ISP while antisense primer amplifies from stop site.


Primers are designed to include a strong KOZAK context (GCCGCCACC)


Sense primer is designed to contain the seguence for IgE leader seguence plus a ATG start site.

Rrimer Name	Sense/Antisense	Sequence 5' to 3'
Human IL-15-laE	sense (SEQ ID NO: 8)	sense (SEQ ID NO: 8)   GCCCCCGAAATTC. GCCGCCACCATGGATTGGACTTGGATCTTATTTTT
	(SEQ ID NO: 9)	<u>AGTTGCTGCTGCTACTAGAGTTCTAACTGGGTGAATGTAATAAGT</u>
	antisense(SEQ ID NO: 5)	Antisense(SEQ ID NO: 5) ATCGGGCTCGAG TCAAGAAGTGTTGATGAACATTTGG
Macaque IL-15-tgE	Sense (SEQ ID NO: 8)	SENSE: (SEQ ID NO. 8) GCCCCCGGAATTC GCCCCACCATGGATTGGACTTGGATCTTATTTT
:	(SEQ ID NO: 9)	AGTTGCTGCTGCTAGTAGAGTTCATTCTAACTGGGTGAATGTAATAAGT
	artisense(SEQ ID NO: 5)	BATTER ID NO: SIATOGGGCTOGAG TOAAGAKGTGTTGATGAACATTTGG

end: Restriction Site, KOZAK, START, STOP CODON

FIGURE 11








FIGURE 12




FIGURE 13

## Immunization Schedule

Immunization Groups:

Naïve

Vector Control
HIV-1 Gag
HIV-1 Gag/ IL15 constructs

Combinations of 100 µg IL15 Constructs, 50 µg GAG, Each injection, intramuscular




FIGURE 14

Restimulation of antigen-specific IFN-γ production 5 Weeks Following the 3rd-immunization of HIV-1 Gag in Balb/C mice




FIGURE 15

An Engineered IL-15 Plasmid Vaccine (Kozak, AUG's removed, UTR's removed & other-30-

50X better expression) Enhances CTL response in Vivo Mice were immunized with HIV-1 gag expressing DNA

層 ■ DNA alone **■** plus IL-15 Gag Lysis **Targets** Control 83 S Specific lysis

Bamford et al., (1998) J. Immunol 160:4418-4426, Kozak et al., (1991) J. Cell Biol. 115:887-903 Grabstein et al. (1994) Science 264:965-968, Bamford et al., 1996) PNAS 93:2897-2902

FIGURE 16

**SUBSTITUTE SHEET (RULE 26)**